Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients must be able to understand and willing to participate in the study, and provide a personally dated and signed written informed consent form.~2. Patients must have a confirmed diagnosis of ET according to the World health Organisation's criteria.~3. ET patients who are uncontrolled, in the Investigator's opinion, by first-line (or previous) cytoreductive treatment for efficacy or tolerance reasons.~4. Patients who have either commenced treatment with anagrelide hydrochloride in the last 7 days or for whom a decision has been documented to commence treatment with anagrelide hydrochloride~Exclusion Criteria:~1. Patients for whom treatment with anagrelide hydrochloride is contraindicated, according to the current XAGRID SmPC.~2. Known or suspected intolerance or hypersensitivity to the product, closely related compounds, or any of the stated ingredients.~3. Patients participating in an interventional research study.~4. Patients on combination therapy or for whom there is an intention to treat with other cytoreductive agents e.g., hydroxyurea, interferon. Patients can however use aspirin and other anti-aggregatory products at the Investigator's discretion.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- JAK2 Positive Participants (Type: None): None
- JAK2 Negative Participants (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).